Fluralaner (Bravecto)

Fluralaner is an isoxazoline class ectoparasiticide marketed under the brand name Bravecto, distinguished by its extended duration of action that provides up to twelve weeks of flea and tick protection from a single dose. This long-acting formulation represents a significant advancement in parasite prevention convenience, reducing the frequency of administration compared to monthly products and potentially improving compliance among pet owners who may forget monthly treatments. Since its FDA approval for veterinary use, fluralaner has become a popular choice for flea and tick control in dogs, offering effective protection with the convenience of quarterly rather than monthly dosing. The medication is available as both flavored chewable tablets for oral administration and as a topical solution for dogs where oral administration may be challenging.

The mechanism of action of fluralaner involves potent inhibition of gamma-aminobutyric acid-gated chloride channels and glutamate-gated chloride channels in the nervous systems of arthropods. These chloride channels are essential for normal neurotransmission in invertebrates, and their blockade by fluralaner causes uncontrolled neuronal stimulation leading to paralysis and death of fleas and ticks. The selectivity of fluralaner for invertebrate chloride channels compared to mammalian channels provides a substantial safety margin for dogs. After oral administration, fluralaner is absorbed into the bloodstream and distributed throughout body tissues, where it remains at therapeutic concentrations for approximately twelve weeks, continuously protecting against parasites that feed on the treated dog.

Bravecto chewable tablets are available in five weight-based formulations to provide accurate dosing across the full size range of dogs. Products are available for dogs weighing 4.4 to 9.9 pounds, 9.9 to 22 pounds, 22 to 44 pounds, 44 to 88 pounds, and 88 to 123 pounds. Each tablet delivers fluralaner at a minimum dose of 25 milligrams per kilogram of body weight. For dogs exceeding 123 pounds, an appropriate combination of tablets is prescribed to achieve the correct total dose. The flavored formulation is designed for high palatability, with most dogs accepting the tablet readily when offered as a treat. Bravecto topical solution provides an alternative for dogs that refuse oral medication or have gastrointestinal conditions that may affect oral drug absorption.

Fluralaner has demonstrated a favorable safety profile in clinical trials and post-market surveillance when used according to label directions. The product is approved for use in dogs and puppies six months of age and older. As with all isoxazoline class medications, potential neurological adverse events have been reported in some dogs, and the FDA has issued a class-wide alert regarding this risk. Veterinary guidance is essential for determining whether fluralaner is appropriate for each individual dog, particularly those with seizure history or neurological conditions. The extended duration of action means that if adverse effects occur, drug levels will persist longer than with monthly products, making careful patient selection particularly important.

The primary indication for fluralaner is the treatment and prevention of flea infestations caused by Ctenocephalides felis, providing up to twelve weeks of protection from a single dose. Fluralaner begins killing fleas within two hours of administration, with greater than ninety-eight percent efficacy against existing infestations achieved within twelve hours. This rapid onset of action quickly eliminates existing flea populations, while the extended duration prevents reinfestation for three months. By killing adult fleas before they can reproduce, fluralaner disrupts the flea life cycle and helps clear environmental infestations in the home over time. The twelve-week dosing interval simplifies flea prevention protocols and may improve compliance compared to monthly products.

Tick prevention and treatment represents an equally important indication for fluralaner. The medication has demonstrated efficacy against multiple tick species of veterinary and public health importance, including the black-legged tick or deer tick (Ixodes scapularis), American dog tick (Dermacentor variabilis), and brown dog tick (Rhipicephalus sanguineus) for the full twelve-week period. Lone Star tick (Amblyomma americanum) protection extends for eight weeks following a dose. Ticks are killed within twelve hours of attachment, reducing the time available for disease transmission. For dogs living in areas endemic for Lyme disease, anaplasmosis, ehrlichiosis, and other tick-borne infections, consistent fluralaner administration provides critical protection with convenient quarterly dosing.

Prevention of flea allergy dermatitis is an important therapeutic application of fluralaner for dogs sensitized to flea saliva proteins. Flea allergy dermatitis causes intense itching, hair loss, and skin inflammation that significantly impacts affected dogs' quality of life. By rapidly killing fleas before they can engage in prolonged feeding, fluralaner prevents the allergic reaction in susceptible dogs. The extended duration of protection is particularly valuable for dogs with flea allergy, as continuous flea control without gaps between doses helps maintain remission of clinical signs. Dogs with severe flea allergy may benefit from additional therapies to address existing skin damage while fluralaner prevents ongoing flea exposure.

Fluralaner has also demonstrated efficacy against demodectic mange caused by Demodex canis mites and sarcoptic mange caused by Sarcoptes scabiei mites. Dogs with generalized demodicosis, a condition that can be challenging to treat with traditional therapies, often show excellent response to fluralaner treatment. The convenience of quarterly dosing compared to daily or weekly treatments with older medications significantly reduces the treatment burden for both dogs and owners. For sarcoptic mange, fluralaner rapidly eliminates the intensely pruritic mite infestation. Additionally, fluralaner has shown efficacy against ear mites (Otodectes cynotis), providing another treatment option for this common parasitic condition.

Veterinarians choose fluralaner when the extended duration of action offers advantages for patient care or owner compliance. Dogs whose owners have difficulty remembering monthly treatments may benefit from the quarterly schedule. The extended efficacy makes fluralaner suitable for dogs at consistent flea and tick exposure who need reliable continuous protection. The availability of both oral and topical formulations provides flexibility in administration route based on individual dog preferences and health status. For dogs requiring mange treatment, the proven efficacy against Demodex and Sarcoptes mites makes fluralaner a convenient alternative to more frequent dosing regimens.

The dosing protocol for fluralaner involves administration of a single oral dose at the minimum rate of 25 milligrams per kilogram of body weight, providing flea and tick protection for up to twelve weeks. Accurate weight measurement is critical for selecting the appropriate product size and ensuring therapeutic efficacy throughout the extended dosing interval. Because fluralaner maintains protective drug levels for three months, accurate initial dosing is particularly important to prevent gaps in coverage as drug levels decline toward the end of the dosing period. Veterinary staff typically weigh dogs at each visit and recommend the correct Bravecto product based on current body weight.

Bravecto chewable tablets are available in five weight-based formulations to accommodate dogs ranging from toy breeds to giant breeds. Dogs weighing 4.4 to 9.9 pounds receive a tablet containing 112.5 milligrams of fluralaner. Dogs weighing 9.9 to 22 pounds receive a tablet containing 250 milligrams of fluralaner. Dogs weighing 22 to 44 pounds receive a tablet containing 500 milligrams of fluralaner. Dogs weighing 44 to 88 pounds receive a tablet containing 1000 milligrams of fluralaner. Dogs weighing 88 to 123 pounds receive a tablet containing 1400 milligrams of fluralaner. Dogs exceeding 123 pounds receive an appropriate combination of tablets to achieve the correct dose based on actual body weight.

The twelve-week dosing interval should be maintained consistently for continuous flea and tick protection. Fluralaner levels in the bloodstream peak within days of administration and then gradually decline over the following weeks while remaining above therapeutic thresholds. By the end of the twelve-week period, levels are approaching the minimum effective concentration, and redosing is necessary to maintain protection. Breaking the dosing schedule or extending intervals beyond twelve weeks may result in gaps in protection where fleas or ticks can establish infestation. Year-round protection requires four doses annually, administered every twelve weeks regardless of season in most geographic areas.

Administration of fluralaner chewable tablets is designed for owner convenience and dog acceptance. The flavored tablet can be given with or without food, though administration with food may improve absorption. Most dogs accept the tablet readily as a treat directly from the owner's hand. For dogs reluctant to accept the tablet, it can be hidden in a small amount of food or a treat-hiding product. The tablet should be consumed whole rather than broken, as the formulation is designed for complete single-dose administration. Owners should observe to ensure the dog chews and swallows the entire dose. For dogs that cannot tolerate oral medication, Bravecto topical solution provides an alternative applied to the skin at the base of the neck.

If the scheduled twelve-week dose is missed, fluralaner should be administered as soon as the missed dose is discovered, and then the quarterly schedule should resume from that date. Dogs that have gone significantly beyond twelve weeks without redosing may have diminished protection and should be monitored for signs of flea or tick infestation. There is no need to administer extra medication to make up for a missed dose. For dogs with known heavy parasite exposure that have missed their redosing window, physical examination for parasites and appropriate intervention if found may be warranted.

Consistent quarterly administration throughout the year provides continuous flea and tick protection without gaps in coverage. Setting calendar reminders for redosing dates helps pet owners maintain the schedule. Many veterinary clinics offer reminder services through postcards, emails, or text messages to alert clients when redosing is due. Because fluralaner is only available by prescription, scheduled veterinary visits may be required to obtain refills, providing opportunities for wellness assessment and weight verification to ensure continued appropriate dosing.

Fluralaner has demonstrated a favorable safety profile in clinical studies and extensive post-market use, with the majority of dogs tolerating the medication well when administered according to label directions. The extended duration of action means that any adverse effects that do occur may persist longer than with monthly products, as fluralaner remains in the body for approximately twelve weeks. Understanding the potential side effects helps pet owners monitor their dogs appropriately and report concerns to their veterinarian in a timely manner.

The most commonly reported side effects of fluralaner in clinical trials were mild gastrointestinal disturbances. Vomiting occurred in a small percentage of dogs following oral administration, typically within the first day and usually resolving without treatment. Diarrhea and decreased appetite were also reported at low rates. Flatulence was observed more frequently in fluralaner-treated dogs compared to controls in some studies. These gastrointestinal effects are generally mild and transient, similar to those seen with other oral medications. Administering fluralaner with a meal may help reduce stomach upset in dogs prone to gastrointestinal sensitivity.

Dermatological effects including itching, redness, and hair loss at sites other than the application area for topical formulation were occasionally reported. As with other ectoparasiticides, some skin effects may represent resolution of pre-existing flea infestation or flea allergy dermatitis rather than true medication side effects. However, new or worsening skin changes should be reported to the veterinarian for evaluation to determine whether they represent a medication reaction, continued parasite problem, or separate dermatological condition requiring attention.

Neurological adverse events represent the most significant safety concern with fluralaner and other isoxazoline class medications. The FDA has issued a class-wide alert regarding potential neurological effects including muscle tremors, ataxia, and seizures. These events have been reported in some dogs receiving fluralaner, including dogs with no prior seizure history. While the incidence appears to be rare relative to the large number of doses administered worldwide, the extended duration of fluralaner in the body means neurological effects could persist for weeks if they occur. Dogs with a history of seizures may be at increased risk, and the use of fluralaner in these patients requires careful veterinary assessment of benefits and risks.

Additional adverse events reported during clinical use include lethargy, decreased activity, and behavioral changes in some dogs. Hypersalivation has been noted in some cases following oral administration. Any persistent changes in behavior, energy level, or overall health should be reported to the veterinarian for evaluation. The extended duration of fluralaner makes patient selection and monitoring particularly important, as effects will persist longer than with monthly alternatives. Most dogs complete fluralaner treatment without experiencing notable adverse effects, but awareness of potential reactions supports appropriate monitoring and timely intervention if needed.

Fluralaner is contraindicated in dogs with known hypersensitivity to fluralaner or other isoxazoline class medications. Dogs that have experienced allergic reactions to Bravecto or similar products such as afoxolaner, sarolaner, or lotilaner should not receive fluralaner. Signs of hypersensitivity may include facial swelling, hives, difficulty breathing, or severe skin reactions developing after administration. Because fluralaner remains in the body for approximately twelve weeks, any allergic reaction could persist for an extended period, making identification of previously sensitive dogs particularly important before prescribing.

Dogs with a history of seizures or neurological disorders warrant careful evaluation before prescribing fluralaner. The FDA has identified potential neurological adverse events, including seizures, associated with isoxazoline class medications. While many dogs with controlled epilepsy have received fluralaner without incident, the extended duration of action means that if neurological effects occur, they could persist for weeks as the drug clears from the body. The decision to prescribe fluralaner to a dog with seizure history should involve thorough discussion between the veterinarian and pet owner regarding potential risks and benefits. Alternative flea and tick prevention methods with shorter durations may be more appropriate for dogs with poorly controlled seizures.

Fluralaner chewable tablets are not approved for use in dogs under six months of age or weighing less than 4.4 pounds. The safety and efficacy of the medication in very young puppies has not been established through clinical trials, and their developing systems may metabolize the medication differently than adult dogs. Very small dogs present dosing challenges with the available product sizes. Bravecto topical solution has different age and weight restrictions; pet owners should verify appropriate formulation selection with their veterinarian based on their dog's age and size.

Breeding, pregnant, and lactating dogs represent populations where fluralaner use requires veterinary consideration. The medication has not been specifically evaluated for safety in breeding males, pregnant females, or lactating females and their nursing puppies. While no specific adverse effects have been documented in these populations, the lack of safety data and the twelve-week persistence of the drug in the body warrant careful consideration. Pet owners planning to breed their dogs should discuss flea and tick prevention timing and product selection with their veterinarian. Complete disclosure of health history, medications, and reproductive status helps the veterinarian make informed recommendations about fluralaner suitability for each individual patient.

Pet owners should provide their veterinarian with a complete list of all medications, supplements, and treatments their dog receives before starting fluralaner therapy. While fluralaner has relatively few documented drug interactions, thorough medication disclosure allows identification of any potential concerns and appropriate treatment planning. The twelve-week duration of fluralaner action means any interactions could be present for an extended period, making comprehensive medication review particularly important. This includes prescription medications, over-the-counter products, herbal supplements, and any other parasite prevention products being used.

Concurrent use of fluralaner with heartworm preventives and other routine medications is common in veterinary practice. Many dogs receive fluralaner for flea and tick prevention while also taking monthly heartworm preventives containing ivermectin, milbemycin oxime, or moxidectin. These combinations are generally considered safe and are frequently prescribed together as part of comprehensive parasite prevention protocols. However, using multiple products with overlapping activity against the same parasites provides no additional benefit and increases cost and medication exposure. The veterinarian can help optimize the parasite prevention regimen to provide necessary protection without redundancy.

Dogs receiving anticonvulsant medications for seizure control represent a population where potential interactions or additive effects deserve consideration. While specific pharmacokinetic interactions between fluralaner and anticonvulsants such as phenobarbital, potassium bromide, or levetiracetam have not been documented, the potential for neurological adverse events with isoxazoline products may be of concern in epileptic patients. Veterinarians may want to monitor seizure control more closely in dogs receiving both fluralaner and anticonvulsants, or may recommend alternative flea and tick prevention for dogs with poorly controlled seizures.

Fluralaner undergoes metabolism in the body, and drugs affecting metabolic enzymes could theoretically alter fluralaner levels or duration of action. Dogs with liver disease may have altered drug metabolism, though clinical studies have not specifically evaluated fluralaner in dogs with hepatic compromise. Similarly, dogs receiving medications known to affect liver enzyme activity could potentially have altered fluralaner processing. The veterinarian can assess whether liver function evaluation is appropriate before prescribing fluralaner to dogs with known or suspected hepatic conditions.

Monitoring during concurrent medication use involves observing for expected therapeutic effects and any unexpected symptoms that might indicate drug interactions. Pet owners should report any changes in behavior, seizure frequency, appetite, activity level, or development of new symptoms after starting fluralaner or adding new medications to their dog's regimen. Because fluralaner persists in the body for twelve weeks, any interaction effects would similarly persist, making early identification and veterinary consultation important for appropriate management.

Standard precautions for fluralaner use include accurate weight-based dosing, adherence to the twelve-week administration schedule, and appropriate patient selection based on health history. Ensuring the correct product size based on current body weight prevents underdosing that could result in inadequate parasite protection or overdosing that wastes medication. Weight verification at each dosing is recommended, particularly for growing dogs whose weight may change significantly over twelve weeks. Following the quarterly dosing schedule maintains continuous protection without gaps when parasites could establish infestation.

The FDA has issued a class-wide alert regarding potential neurological adverse events associated with isoxazoline products, including fluralaner. Reported events include muscle tremors, ataxia, and seizures in some dogs, including those with no prior seizure history. The extended duration of fluralaner in the body is an important consideration when evaluating this risk, as neurological effects could potentially persist for weeks if they occur. Pet owners should be informed of this potential and should monitor their dogs following administration, seeking immediate veterinary attention if neurological signs develop. For dogs with pre-existing seizure disorders, the veterinarian will carefully weigh the benefits of extended flea and tick protection against potential neurological risks.

Environmental considerations for fluralaner differ between oral and topical formulations. For the chewable tablet, there are no residue concerns for households with children, and dogs can bathe, swim, and be groomed without affecting efficacy. However, the flavored tablets should be stored securely away from children and pets to prevent accidental ingestion. The twelve-week supply represented by a single tablet makes accidental consumption by another pet potentially serious, and secure storage is essential. For the topical formulation, standard precautions regarding contact with application site until dry apply.

Monitoring for efficacy throughout the twelve-week dosing interval helps identify any treatment failures that could indicate resistance, heavy environmental challenge, or product issues. While fluralaner maintains protective levels throughout the labeled period, periodic inspection of dogs for fleas or ticks, particularly during peak season, confirms adequate protection. Finding parasites on a treated dog despite appropriate dosing may indicate environmental factors requiring additional intervention or could signal resistance developing in local parasite populations.

Special populations requiring additional consideration include senior dogs with age-related changes in organ function, dogs with chronic health conditions, and dogs receiving multiple long-term medications. While fluralaner is generally well tolerated across age ranges, comprehensive health assessment helps identify patients who may be at increased risk for adverse effects. Working dogs, performance dogs, and dogs in breeding programs may have specific considerations influencing product selection. The twelve-week duration makes fluralaner commitment more significant than monthly products, and careful patient selection ensures the choice is appropriate for each individual dog's circumstances.

Proper storage of fluralaner products maintains medication quality throughout the extended period between doses and prevents accidental ingestion by children or pets. Bravecto chewable tablets should be stored at controlled room temperature, generally between 68 and 77 degrees Fahrenheit, though brief temperature excursions between 59 and 86 degrees Fahrenheit as occur during normal household conditions are acceptable. Extreme temperatures should be avoided. Excessive heat could affect the tablet formulation, while freezing is not recommended. A dry location away from humidity helps maintain product integrity.

Bravecto chewable tablets are packaged individually in sealed containers to maintain product quality and prevent degradation from moisture or air exposure. The packaging clearly identifies the product formulation and weight range, allowing verification of appropriate product selection before administration. Each package contains a single dose designed to provide twelve weeks of protection, representing a significant medication commitment in a single unit. The packaging should remain intact until administration time to protect the tablet from environmental exposure.

Secure storage location is critically important for fluralaner because the flavored formulation is designed to be palatable to dogs. A single Bravecto tablet contains the dog's entire twelve-week dose, and accidental ingestion by another pet could result in significant overdose. Dogs should not have unsupervised access to areas where the medication is stored. Appropriate storage locations include locked cabinets, high shelves inaccessible to pets, or closed medication storage containers. In multi-pet households, products for different weight dogs should be clearly organized to prevent administration errors.

Bravecto topical solution has specific storage requirements that may differ from the chewable formulation. The topical product should be stored according to package directions, typically at room temperature protected from light. The applicator tube should remain sealed until use. Once opened, the topical solution should be applied promptly rather than stored for later use. Any unused topical solution should be disposed of appropriately rather than saved.

Disposal of unused or expired fluralaner should follow local guidelines for pharmaceutical waste disposal. Expired medication may have reduced efficacy and should not be administered. Many communities offer pharmaceutical take-back programs accepting veterinary medications. If take-back programs are unavailable, the medication can typically be mixed with an undesirable substance such as coffee grounds and placed in a sealed container in household trash. Empty packaging should be disposed of according to local recycling guidelines after ensuring no medication residue remains. The veterinarian or local pharmacy can provide specific guidance on proper disposal methods.

Fluralaner can be safely used in dogs of all breeds, as the medication is not affected by breed-specific genetic variations that impact some other antiparasitic drugs. Unlike ivermectin and related macrocyclic lactones that can cause toxicity in dogs with the MDR1 gene mutation, fluralaner works through a different mechanism not involving P-glycoprotein transport. This means Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and other herding breeds affected by MDR1 mutations can receive fluralaner at standard doses for flea and tick prevention. The isoxazoline class represents an important safe alternative for these breeds when broad-spectrum ectoparasite control is needed.

While MDR1 sensitivity is not a concern with fluralaner, the potential for neurological adverse events with isoxazoline products applies across all breeds. The FDA alert regarding seizures and other neurological effects does not identify specific breeds at elevated risk. However, breeds with known predisposition to epilepsy should have their seizure history carefully evaluated before prescribing fluralaner. Breeds with higher epilepsy prevalence include Belgian Tervurens, Irish Wolfhounds, English Springer Spaniels, Vizslas, Bernese Mountain Dogs, and several others. Individual dogs of any breed with seizure history require careful assessment of the risk-benefit ratio before starting isoxazoline therapy.

Size considerations affect product selection but not fundamental safety. Toy breeds must be accurately weighed to ensure appropriate product selection, as the smallest Bravecto chewable is designed for dogs weighing at least 4.4 pounds. Very small dogs at the minimum weight may need weight verification before each quarterly dose to ensure continued appropriateness. Giant breeds exceeding 123 pounds require combination dosing with multiple tablets to achieve the correct total dose based on body weight, with specific guidance from the veterinarian on appropriate product combinations. The twelve-week dosing interval makes accurate initial dosing particularly important.

Age considerations for fluralaner span all breeds. The chewable formulation is approved for dogs six months of age and older, meaning younger puppies must use alternative flea and tick protection until they reach appropriate age. Growing puppies approaching the six-month threshold should have their age and weight verified before starting fluralaner. Senior dogs may have age-related changes in metabolism that could affect drug processing, though fluralaner is generally well tolerated in older dogs. Dogs of any age with concurrent health conditions should have their overall status evaluated when making flea and tick prevention decisions, with particular attention to any history of neurological conditions given the class-wide FDA alert.

Within the isoxazoline class of oral ectoparasiticides, several alternatives to fluralaner exist with different dosing intervals and formulations. Afoxolaner, marketed as NexGard, provides monthly flea and tick protection and may be preferred for owners who want more frequent dosing flexibility or for dogs where the twelve-week fluralaner duration represents concerns regarding the persistence of potential adverse effects. Sarolaner, sold as Simparica, offers monthly protection with additional label claims against mites. Lotilaner, marketed as Credelio, is another monthly option in the isoxazoline class. The choice among these products often depends on owner preference regarding dosing frequency, specific parasites of concern, and individual dog tolerance.

Non-isoxazoline alternatives provide options for flea and tick prevention through different mechanisms. Spinosad, available as Comfortis, offers monthly oral flea control but lacks tick efficacy. Topical products containing fipronil, permethrin, or imidacloprid provide external application alternatives for owners preferring non-oral routes or for dogs unable to receive isoxazoline medications. Long-lasting flea and tick collars offer extended protection through different active ingredients. Each alternative has specific advantages, limitations, and safety considerations that the veterinarian can discuss when determining the most appropriate choice for each individual dog.

Combination products incorporating fluralaner with additional active ingredients provide expanded parasite coverage. Bravecto Plus for dogs combines fluralaner with moxidectin to add heartworm prevention and treatment of certain intestinal parasites to the flea and tick protection. This combination simplifies parasite prevention by addressing multiple parasite types with quarterly dosing. The decision between combination products and separate medications depends on the specific parasites relevant to the dog's geographic location and lifestyle, existing prevention protocols, cost considerations, and owner preference.

Complementary approaches to flea and tick control may enhance fluralaner efficacy in heavily infested environments. Environmental treatment of homes and yards reduces parasite populations and decreases reinfestation pressure on treated dogs. Regular grooming and inspection helps identify any parasites that may attach between treatments. For dogs with flea allergy dermatitis, additional skin treatments may be needed alongside flea prevention to manage allergic symptoms while the condition resolves. The veterinarian can develop a comprehensive parasite management strategy incorporating fluralaner as one component of an integrated approach tailored to each dog's specific exposure risks and health needs.